- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01319214
Reducing Drug Craving Memories
May 18, 2011 updated by: McGill University Health Centre/Research Institute of the McGill University Health Centre
Reconsolidation as a Treatment Target for Cocaine Addiction
The primary objective is to investigate the potential ability of Inderal (propranolol hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in cocaine dependent participants.
If effective in this laboratory model, Inderal may have clinical efficacy.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 46 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 60 psychotropic medication-free men or women (15 subjects x 4 groups) who have met DSM-IV-TR diagnostic criteria for cocaine dependence for the past 6 months (age 18 - 50 years old);
- Minimum of three days cocaine abstinent on study days;
- Primary use of cocaine is intra-nasal or smoked crack
Exclusion Criteria:
Medical conditions that might be aggravated by participation in the study:
- cardiovascular disorders that might be aggravated by participation in the study: hypotension (SBP: < 100 mmHg), bradycardia (heart rate < 60 /min), severe atrioventricular block (Type II or III), severe hypertension (SBP: > 160 mmHg; DBP: > 100 mmHg), myocardial infarction, history of chest pain and admission to ED for chest pain;
- respiratory disorders: bronchial asthma and chronic obstructive pulmonary disease;
- diabetic patients treated with insulin or oral hypoglycemic agents. Propranolol may mask the first signs of a developing hypoglycemia.
- Seropositive pregnancy test
- Comorbidity with current axis I psychiatric disorders other than anxiety, affective and substance use disorders
- Severe liver disfunction
- Current or recent (< 5 half lives) use of medications that may interact with Inderal (see above)
- Positive urine tox screen for barbiturates. Positive breath alcohol screen. {Note: all urine tox screen results will be destroyed immediately after collection. The information will not be stored}
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Inderal, neutral cues
|
Inderal vs. placebo will be administered with or without cocaine cues
|
|
Experimental: Inderal, drug cues
|
Inderal vs. placebo will be administered with or without cocaine cues
|
|
Experimental: Placebo, neutral cues
|
Inderal vs. placebo will be administered with or without cocaine cues
|
|
Experimental: Placebo, drug cues
|
Inderal vs. placebo will be administered with or without cocaine cues
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-report drug craving
Time Frame: One day and one month post-treatment
|
One day and one month after the intervention, the investigators will measure drug craving using visual analog scales (VAS) and the Cocaine Craving Questionnaire (CCQ).
|
One day and one month post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Drug use
Time Frame: One month after the intervention
|
One month after the intervention, participants will be interviewed about their drug and alcohol use
|
One month after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Anticipated)
March 1, 2015
Study Completion (Anticipated)
March 1, 2015
Study Registration Dates
First Submitted
March 18, 2011
First Submitted That Met QC Criteria
March 18, 2011
First Posted (Estimate)
March 21, 2011
Study Record Updates
Last Update Posted (Estimate)
May 19, 2011
Last Update Submitted That Met QC Criteria
May 18, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Compulsive Behavior
- Impulsive Behavior
- Behavior, Addictive
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Propranolol
Other Study ID Numbers
- 10-039-PSY
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.